Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ. Welch JS, et al. Among authors: petti aa. N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949. N Engl J Med. 2016. PMID: 27959731 Free PMC article. Clinical Trial.
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.
Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S, Wartman LD, Christopher M, Lamprecht TL, Helton NM, Duncavage EJ, Payton JE, Baty J, Heath SE, Griffith OL, Shen D, Hundal J, Chang GS, Fulton R, O'Laughlin M, Fronick C, Magrini V, Demeter RT, Larson DE, Kulkarni S, Ozenberger BA, Welch JS, Walter MJ, Graubert TA, Westervelt P, Radich JP, Link DC, Mardis ER, DiPersio JF, Wilson RK, Ley TJ. Klco JM, et al. JAMA. 2015 Aug 25;314(8):811-22. doi: 10.1001/jama.2015.9643. JAMA. 2015. PMID: 26305651 Free PMC article.
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
Duncavage EJ, Uy GL, Petti AA, Miller CA, Lee YS, Tandon B, Gao F, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Jacoby MA, Cashen AF, Wartman LD, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ, Welch JS. Duncavage EJ, et al. Among authors: petti aa. Blood. 2017 Mar 9;129(10):1397-1401. doi: 10.1182/blood-2016-10-745273. Epub 2017 Jan 12. Blood. 2017. PMID: 28082444 Free PMC article. Clinical Trial. No abstract available.
Decitabine in TP53-Mutated AML.
Welch JS, Petti AA, Ley TJ. Welch JS, et al. Among authors: petti aa. N Engl J Med. 2017 Feb 23;376(8):797-8. doi: 10.1056/NEJMc1616062. N Engl J Med. 2017. PMID: 28225682 No abstract available.
Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies.
Cole CB, Russler-Germain DA, Ketkar S, Verdoni AM, Smith AM, Bangert CV, Helton NM, Guo M, Klco JM, O'Laughlin S, Fronick C, Fulton R, Chang GS, Petti AA, Miller CA, Ley TJ. Cole CB, et al. Among authors: petti aa. J Clin Invest. 2017 Oct 2;127(10):3657-3674. doi: 10.1172/JCI93041. Epub 2017 Sep 5. J Clin Invest. 2017. PMID: 28872462 Free PMC article.
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.
Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O'Laughlin M, Fronick CC, Fulton RS, Wilson RK, Wartman LD, Welch JS, Heath SE, Baty JD, Payton JE, Graubert TA, Link DC, Walter MJ, Westervelt P, Ley TJ, DiPersio JF. Christopher MJ, et al. Among authors: petti aa. N Engl J Med. 2018 Dec 13;379(24):2330-2341. doi: 10.1056/NEJMoa1808777. Epub 2018 Oct 31. N Engl J Med. 2018. PMID: 30380364 Free PMC article.
Remethylation of Dnmt3a-/- hematopoietic cells is associated with partial correction of gene dysregulation and reduced myeloid skewing.
Ketkar S, Verdoni AM, Smith AM, Bangert CV, Leight ER, Chen DY, Brune MK, Helton NM, Hoock M, George DR, Fronick C, Fulton RS, Ramakrishnan SM, Chang GS, Petti AA, Spencer DH, Miller CA, Ley TJ. Ketkar S, et al. Among authors: petti aa. Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):3123-3134. doi: 10.1073/pnas.1918611117. Epub 2020 Jan 29. Proc Natl Acad Sci U S A. 2020. PMID: 31996479 Free PMC article.
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.
Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Foltz JA, et al. Among authors: petti aa. Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. Epub 2021 Apr 8. Clin Cancer Res. 2021. PMID: 33832946 Free PMC article. Clinical Trial.
38 results